Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026)
Ovid Therapeutics (OVID) posted Income from Continuing Operations of 16988000.0 for Q1 2026, down 275.8% on a QoQ basis from 9663000.0 in Q4 2025, and down 65.98% year-over-year from 49934572.09 in Q1 2025.
Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 16988000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 65.98% year-over-year to 16988000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24167000.0 (up 3.23% YoY) and the FY2025 annual result came in at 17414000.0, up 34.12% from the prior year.
- Income from Continuing Operations was 16988000.0 for Q1 2026 at Ovid Therapeutics, down from 9663000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9663000.0 in Q4 2025 and bottomed at 16988000.0 in Q1 2026.
- A 5-year average of 9843648.82 and a median of 11967771.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 204.43% in 2025, while the deepest fall reached 154.97% in 2025.
- Ovid Therapeutics' Income from Continuing Operations stood at 11504789.0 in 2022, then tumbled by 33.18% to 15322000.0 in 2023, then surged by 39.61% to 9253000.0 in 2024, then surged by 204.43% to 9663000.0 in 2025, then plunged by 275.8% to 16988000.0 in 2026.
- Business Quant data shows OVID's Income from Continuing Operations at 16988000.0 in Q1 2026, 9663000.0 in Q4 2025, and 12158000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,023.69 Bn | 1,023.69 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 468.59 Bn | 463.80 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.01 Bn | 115.76 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.29 Bn | 61.53 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.33 Bn | 63.33 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.70 Bn | 50.52 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ovid Therapeutics | 121.66 Mn | -33.86 Mn | - | -16.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.99 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | -12.16 Mn |
| Jun 30, 2025 | -4.68 Mn |
| Mar 31, 2025 | -10.24 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | 8.52 Mn |
| Mar 31, 2024 | -11.69 Mn |
| Dec 31, 2023 | -15.32 Mn |
| Sep 30, 2023 | -11.25 Mn |
| Jun 30, 2023 | -12.41 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Dec 31, 2022 | -11.50 Mn |
| Sep 30, 2022 | -11.97 Mn |
| Jun 30, 2022 | -14.59 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -11.38 Mn |
| Jun 30, 2021 | -15.79 Mn |